Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1084 plus durvalumab versus placebo plus durvalumab after concurrent chemoradiotherapy in KRAS G12C-mutated unresectable stage II-III non-small cell lung cancer
NL-OMON61245Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-1084 plus durvalumab with Placebo plus durvalumab (2 arms). Primary endpoint: Progression-Free Survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
calderasibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61245.